MARKET

ARMP

ARMP

Armata Pharmaceuticals Inc
AMEX

Real-time Quotes | Nasdaq Last Sale

4.130
-0.320
-7.19%
After Hours: 4.050 -0.08 -1.94% 16:16 02/21 EST
OPEN
4.530
PREV CLOSE
4.450
HIGH
4.530
LOW
4.070
VOLUME
66.16K
TURNOVER
--
52 WEEK HIGH
6.92
52 WEEK LOW
2.450
MARKET CAP
41.53M
P/E (TTM)
-1.0784
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of ARMP and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 3 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average ARMP stock price target is 8.83 with a high estimate of 9.50 and a low estimate of 8.00.

EPS

ARMP News

More
  • Armata Pharmaceuticals Announces Closing of First Tranche of Recently Executed $25 Million Securities Purchase Agreement with Innoviva, Inc.
  • PR Newswire · 02/13 13:00
  • Maxim Group Initiates Coverage On Armata Pharmaceuticals with Buy Rating, Announces $8 Price Target
  • Benzinga · 02/06 13:07
  • MMLP, I, NNVC and ARAY among midday movers
  • Seeking Alpha - Article · 01/29 17:40
  • MMLP, XLNX among premarket losers
  • Seeking Alpha - Article · 01/29 14:12

Industry

Biotechnology & Medical Research
+0.06%
Pharmaceuticals & Medical Research
+0.70%

Hot Stocks

Symbol
Price
%Change
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%

About ARMP

Armata Pharmaceuticals, Inc., formerly AmpliPhi Biosciences Corporation, is a biotechnology company. The Company is focused on the discovery, development and commercialization of phage therapeutics. The Company is engaged in identifying, characterizing and developing naturally occurring bacteriophages with its collaboration partners in bacteriophage biology, synthetic biology and manufacturing, to develop second-generation bacteriophage products. The Company is engaged in developing these phage product candidates using a discovery and development platform, which is designed for identification, characterization and manufacturing of multiple phage therapies. Each product candidate combines several chosen phages, which target a specific disease-causing bacterial pathogen, such as staphylococcus aureus (S. aureus), Pseudomonas aeruginosa (P. aeruginosa) and clostridium difficile (C. difficile). Its product candidates are AB-SA01 and AB-PA01.
More

Webull offers kinds of Armata Pharmaceuticals Inc stock information, including AMEX:ARMP real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ARMP stock news, and many more online research tools to help you make informed decisions.